Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era

The clinical outcome of patients with human epidermal growth factor receptor 2 (HER2) amplified breast carcinoma (BC) has improved with the development of anti-HER2 targeted therapies. However, patients can experience disease recurrence after curative intent and disease progression in the metastatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Mandó, Pablo, Rivero, Sergio G., Rizzo, Manglio M., Pinkasz, Marina, Levy, Estrella M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399304/
https://www.ncbi.nlm.nih.gov/pubmed/34454323
http://dx.doi.org/10.1016/j.breast.2021.08.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399304/
https://www.ncbi.nlm.nih.gov/pubmed/34454323
http://dx.doi.org/10.1016/j.breast.2021.08.007

Ejemplares similares